New Delhi: In a major setback to pharmaceutical companies, the Supreme Court on Thursday held that asthma medicine Doxofylline is a bulk drug whose price is to be fixed by the Centre. "We hold that Doxofylline is derivative of Theophylline, a bulk drug, and Doxofylline in any formulation comes within the definition of scheduled formulation. We hold that it is well within the jurisdiction of the government to fix the ceiling price of Doxofylline formulation," a bench of justices G S Singhvi and S J Mukhopadhaya said.
Marriage between first cousins ups risk of having baby with birth defects
Soon, nasal spray that could put an end to painful dentist injections